Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2321Neoplasms 1688Prostatic Neoplasms 1187Lung Neoplasms 914Colorectal Neoplasms 875Carcinoma, Non-Small-Cell Lung 849Leukemia, Myeloid, Acute 585Pancreatic Neoplasms 573Multiple Myeloma 545Carcinoma, Hepatocellular 515Brain Neoplasms 513Neoplasm Metastasis 462Head and Neck Neoplasms 459Melanoma 414Ovarian Neoplasms 409Glioblastoma 399Precursor Cell Lymphoblastic Leukemia-Lymphoma 388Stomach Neoplasms 371Uterine Cervical Neoplasms 359Squamous Cell Carcinoma of Head and Neck 356Rectal Neoplasms 335Recurrence 334Hematologic Neoplasms 327Sarcoma 324Lymphoma 314Colonic Neoplasms 314Triple Negative Breast Neoplasms 285Urinary Bladder Neoplasms 283Glioma 278Carcinoma, Renal Cell 278

Interventions

trifluridine tipiracil drug combination 1Nivolumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Microsatellite-stable Colorectal Cancer × 1 year × Clear all
NCT07011550 2026-03-20

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Suspended
7 enrolled
Gastrointestinal

Microsatellite-stable Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡